Clinical Trials Logo

Thyroid Eye Disease clinical trials

View clinical trials related to Thyroid Eye Disease.

Filter by:

NCT ID: NCT06248619 Recruiting - Thyroid Eye Disease Clinical Trials

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Start date: June 21, 2024
Phase: Phase 3
Study type: Interventional

The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.

NCT ID: NCT06235372 Not yet recruiting - Thyroid Eye Disease Clinical Trials

Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease

Start date: March 21, 2024
Phase:
Study type: Observational

To investigate corneal endothelial cell layer damage by specular microscopy in patients with thyroid eye disease

NCT ID: NCT06226545 Recruiting - Eye Diseases Clinical Trials

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Start date: March 5, 2024
Phase: Phase 2
Study type: Interventional

LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED). The primary and secondary objectives of this study are to evaluate the safety, efficacy, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.

NCT ID: NCT06179875 Recruiting - Thyroid Eye Disease Clinical Trials

An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Start date: February 1, 2023
Phase: Phase 3
Study type: Interventional

An open-label study for participants who are non-responders at end of the treatment period assessment (i.e., 15 weeks) in the VRND-001-101 (THRIVE) and VRDN-001-301 (THRIVE-2) pivotal studies

NCT ID: NCT06112340 Recruiting - Eye Diseases Clinical Trials

A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Start date: October 11, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

NCT ID: NCT06106828 Recruiting - Thyroid Eye Disease Clinical Trials

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2)

SatraGO-2
Start date: November 15, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

NCT ID: NCT06088979 Recruiting - Thyroid Eye Disease Clinical Trials

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease

spiriTED
Start date: February 19, 2024
Phase: Phase 2
Study type: Interventional

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

NCT ID: NCT06021054 Recruiting - Thyroid Eye Disease Clinical Trials

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

Start date: November 14, 2023
Phase: Phase 3
Study type: Interventional

A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001 in participants with chronic thyroid eye disease (TED)

NCT ID: NCT05987423 Recruiting - Thyroid Eye Disease Clinical Trials

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease

Start date: October 26, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

NCT ID: NCT05795621 Completed - Thyroid Eye Disease Clinical Trials

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

Start date: February 14, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease. Approximately 114 subjects meeting study eligibility criteria will be randomly assigned to IBI311 or placebo on day 1 (D1) in a 2:1 ratio stratified by smoking status